Genetic and Phenotypic Characteristics of Mitral Valve Prolapse

NCT ID: NCT03884426

Last Updated: 2021-08-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-12-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phenotypic characterisation of MVP by echocardiography in families. Identification of genes involved in MVP.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After clinical identification of patients with MVP, doctors organize 1st degree relative familial screening. A comprehensive echocardiography was carried out along with clinical examination. All echo data were stored for off-line analysis by a sonographer in our Core-lab. Blood was sample at the time of echocardiography in adult patients for DNA analyses. Follow-up for mitral valve changes will be performed after 5 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mitral Valve Prolapse Genetic Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with MVP

The patients concerned are patients with known or recently discovered Barlow-type mitral prolapse, whatever the degree of severity.

No interventions assigned to this group

Normal relatives

Related healthy patients, for an average of 6 individuals per family

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of any age
* with typical mitral valve prolapse
* relatives examined during familial screening

Exclusion Criteria

* Refusal of the patient
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Brest

OTHER

Sponsor Role collaborator

Rennes University Hospital

OTHER

Sponsor Role collaborator

Nantes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vincent Probst, PU-PH

Role: PRINCIPAL_INVESTIGATOR

Nantes University Hospital

Hervé Le Marec, PU-PH

Role: PRINCIPAL_INVESTIGATOR

Nantes University Hospital

Jean-Jacques Schott, DR

Role: PRINCIPAL_INVESTIGATOR

Institut National de la Santé Et de la Recherche Médicale, France

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Brest University Hospital

Brest, , France

Site Status NOT_YET_RECRUITING

Nantes University Hospital

Nantes, , France

Site Status RECRUITING

Rennes University Hospital

Rennes, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Thierry Le Tourneau, PU-PH

Role: CONTACT

0617908670

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jacques Mansourati, PU-PH

Role: primary

02 98 34 73 91

Thierry Le Tourneau, PU-PH

Role: primary

0617908670

Erwan Donal, PU-PH

Role: primary

02 99 28 25 27

References

Explore related publications, articles, or registry entries linked to this study.

Huttin O, Girerd N, Jobbe-Duval A, Constant Dit Beaufils AL, Senage T, Filippetti L, Cueff C, Duarte K, Fraix A, Piriou N, Mandry D, Pace N, Le Scouarnec S, Capoulade R, Echivard M, Sellal JM, Marrec M, Beaumont M, Hossu G, Trochu JN, Sadoul N, Marie PY, Guenancia C, Schott JJ, Roussel JC, Serfaty JM, Selton-Suty C, Le Tourneau T. Machine Learning-Based Phenogrouping in MVP Identifies Profiles Associated With Myocardial Fibrosis and Cardiovascular Events. JACC Cardiovasc Imaging. 2023 Oct;16(10):1271-1284. doi: 10.1016/j.jcmg.2023.03.009. Epub 2023 May 17.

Reference Type DERIVED
PMID: 37204382 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RC12_0143

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Genetics of QT Response to Moxifloxacin
NCT01936480 TERMINATED PHASE4